4D Molecular Therapeutics Inc (NASDAQ: FDMT) is -56.42% lower on its value in year-to-date trading and has touched a low of $7.32 and a high of $36.25 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The FDMT stock was last observed hovering at around $8.02 in the last trading session, with the day’s gains setting it 0.81%.
Currently trading at $8.83, the stock is 7.24% and -14.31% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.42 million and changing 10.10% at the moment leaves the stock -56.74% off its SMA200. FDMT registered -20.16% loss for a year compared to 6-month loss of -65.15%. The firm has a 50-day simple moving average (SMA 50) of $10.3048 and a 200-day simple moving average (SMA200) of $20.41265.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a 4.50% gain in the last 1 month and extending the period to 3 months gives it a -39.97%, and is 8.74% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.28% over the week and 5.91% over the month.
4D Molecular Therapeutics Inc (FDMT) has around 147 employees, a market worth around $449.42M and $21.99M in sales. Profit margin for the company is -436.30%. Distance from 52-week low is 20.63% and -75.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-16.75%).
with sales reaching $2.2M over the same period.The EPS is expected to shrink by -10.72% this year, but quarterly earnings will post -92.60% year-over-year. Quarterly sales are estimated to grow 11,682.47% in year-over-year returns.
4D Molecular Therapeutics Inc (FDMT) Top Institutional Holders
215.0 institutions hold shares in 4D Molecular Therapeutics Inc (FDMT), with institutional investors hold 132.51% of the company’s shares. The shares outstanding are 51.97M, and float is at 43.91M with Short Float at 18.63%. Institutions hold 127.33% of the Float.
The top institutional shareholder in the company is RA CAPITAL MANAGEMENT, L.P. with over 5.1 million shares valued at $107.01 million. The investor’s holdings represent 10.3471% of the FDMT Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 4.9 million shares valued at $102.79 million to account for 9.9385 of the shares outstanding. The other top investors are VR ADVISER, LLC which holds 4.4 million shares representing 8.93% and valued at over $92.36 million, while GOLDMAN SACHS GROUP INC holds 8.3907 of the shares totaling 4.13 million with a market value of $86.78 million.
4D Molecular Therapeutics Inc (FDMT) Insider Activity
The most recent transaction is an insider sale by Bizily Scott, the company’s Chief Legal Officer. SEC filings show that Bizily Scott sold 500 shares of the company’s common stock on Sep 16 ’24 at a price of $16.33 per share for a total of $8165.0. Following the sale, the insider now owns 6781.0 shares.
4D Molecular Therapeutics Inc disclosed in a document filed with the SEC on Aug 19 ’24 that Bizily Scott (Chief Legal Officer) sold a total of 500 shares of the company’s common stock. The trade occurred on Aug 19 ’24 and was made at $15.00 per share for $7500.0. Following the transaction, the insider now directly holds 6781.0 shares of the FDMT stock.
Still, SEC filings show that on Jul 16 ’24, Bizily Scott (Chief Legal Officer) disposed off 1,750 shares at an average price of $27.11 for $47442.0. The insider now directly holds 6,781 shares of 4D Molecular Therapeutics Inc (FDMT).
